Olema Pharmaceuticals, Inc. (OLMA) 股票分析

公司概述

Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies specifically targeting women's cancers. The company functions within the Healthcare sector and the Biotechnology industry, positioning it as a specialized entity focused on advancing specific therapeutic modalities rather than broad pharmaceutical distribution. Its current market capitalization stands at $1.19B, while the company employs 131 individuals to execute its research and development initiatives. Although the trailing twelve-month revenue is not disclosed in the available data, the market cap indicates that the market values the company's pipeline assets significantly, suggesting that its potential future commercialization of lead candidates like palazestrant is priced in rather than current sales performance.

财务健康

The company reported a net income of $-162,451,008 for the trailing twelve months, alongside an EBITDA of $-168,208,000, while specific revenue figures are not provided in the current dataset. The substantial gap between the reported net income loss and the EBITDA loss highlights a significant cost structure dominated by non-cash expenses such as stock-based compensation or impairment charges, which are common in clinical-stage biotechnology firms but impact the bottom line more severely than operating cash generation. Free cash flow stands at $-82,896,248, indicating a continued burn rate that requires ongoing capital infusion from external financing or existing cash reserves to sustain operations. The balance sheet shows a cash balance of $505.44M against total debt of $4.19M, resulting in a debt-to-equity ratio of 0.88. This disparity between liquid assets and liabilities suggests a highly conservative balance sheet with minimal leverage risk despite the operational losses. The current ratio is listed at 9.95, a figure that indicates an extremely strong short-term liquidity position, allowing the firm to cover its current obligations nearly ten times over with existing current assets. Return on Equity is reported at -36.6% and Return on Assets at -21.4%, metrics that reveal that management has not yet generated positive returns on shareholder or asset investments due to the pre-commercialization nature of the business model.

估值评估

The trailing P/E ratio is listed as N/A due to the lack of positive earnings, while the forward P/E is calculated at -5.37, reflecting the expectation of continued losses in the near term. The price-to-book ratio is 2.32, which indicates that the market is valuing the company at more than double its book value, a premium often attributed to the high value placed on the company's intellectual property and clinical pipeline potential. Alternative valuation metrics such as price-to-sales and EV/EBITDA are also N/A or negative (-4.10 respectively), suggesting that traditional earnings-based multiple comparisons are not applicable at this stage of development. The stock has exhibited significant volatility, trading between a 52-week high of $36.26 and a 52-week low of $2.86. The current market price sits well below the 52-week high, reflecting recent market sentiment shifts or specific company developments that have depressed the share price from its annual peak. The beta value is 2.02, indicating that the stock price is expected to be approximately twice as volatile as the broader market, exposing investors to higher risk in exchange for potential upside if the clinical trials succeed.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated sufficient commercial revenue to calculate meaningful growth rates in the available data. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue, as the fundamental metrics required for such a comparison are currently unavailable. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This non-dividend status implies that the company retains all available capital, if any, to reinvest into research, development, and clinical trials rather than distributing income to shareholders. The overall growth and income profile is characterized by a reliance on future clinical milestones for value creation, with no current income generation or dividend distribution capability to support shareholder returns in the present period.